Gulley JL - Search Results

1

Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.

Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W. Figg WD, et al. Among authors: gulley jl. BJU Int. 2007 May;99(5):1047-55. doi: 10.1111/j.1464-410X.2007.06763.x. BJU Int. 2007. PMID: 17437439 Clinical Trial.

2

Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.

Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY. Zhu M, et al. Cancer Res. 2001 May 1;61(9):3725-34. Cancer Res. 2001. PMID: 11325845

3

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. von Mehren M, et al. Clin Cancer Res. 2001 May;7(5):1181-91. Clin Cancer Res. 2001. PMID: 11350882 Clinical Trial.

4

The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.

Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J. Tsang KY, et al. Cancer Res. 2001 Oct 15;61(20):7568-76. Cancer Res. 2001. PMID: 11606396

5

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. Figg WD, et al. Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6. doi: 10.1016/s0093-7754(01)90157-5. Semin Oncol. 2001. PMID: 11685731 Clinical Trial.

6

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Gulley J, et al. Prostate. 2002 Oct 1;53(2):109-17. doi: 10.1002/pros.10130. Prostate. 2002. PMID: 12242725 Clinical Trial.

7

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.

Horne MK 3rd, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL. Horne MK 3rd, et al. Pharmacotherapy. 2003 Mar;23(3):315-8. doi: 10.1592/phco.23.3.315.32106. Pharmacotherapy. 2003. PMID: 12627929

8

Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.

Behrens RJ, Gulley JL, Dahut WL. Behrens RJ, et al. Among authors: gulley jl. Am J Ther. 2003 May-Jun;10(3):228-32. doi: 10.1097/00045391-200305000-00011. Am J Ther. 2003. PMID: 12756431

9

The emerging role of bisphosphonates in prostate cancer.

Posadas EM, Dahut WL, Gulley J. Posadas EM, et al. Am J Ther. 2004 Jan-Feb;11(1):60-73. doi: 10.1097/00045391-200401000-00012. Am J Ther. 2004. PMID: 14704597 Review.

10

Novel therapeutic strategies in prostate cancer.

Retter AS, Gulley JL, Dahut WL. Retter AS, et al. Among authors: gulley jl. Cancer Biol Ther. 2004 Apr;3(4):371-6. doi: 10.4161/cbt.3.4.725. Epub 2004 Apr 29. Cancer Biol Ther. 2004. PMID: 14726702 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

388 results

Search Page

Filters